Patient Blood Type Is Associated With Response to Immune Checkpoint Blockade in Metastatic Cancer

BACKGROUND: Immune checkpoint blockade (ICB) has transformed cancer therapy, with long-term responses and a favorable safety profile; however, only a minority of patients respond. Response to ICB is influenced by immune-related genetic factors such as HLA haplotype, potentially including patient blo...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Ruifeng, Hakimi, Kasim, Zhang, Xinlian, Messer, Karen, Patel, Sandip Pravin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Immuno-Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9438912/
https://www.ncbi.nlm.nih.gov/pubmed/35816018
http://dx.doi.org/10.1093/oncolo/oyac128

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9438912/
https://www.ncbi.nlm.nih.gov/pubmed/35816018
http://dx.doi.org/10.1093/oncolo/oyac128

Ejemplares similares